RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Anti-Inflammatory
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Pharmacology Channel

subscribe to Pharmacology newsletter
Latest Research : Pharmacology

   EMAIL   |   PRINT
Metal-based medicine could treat diseases

Sep 21, 2005 - 7:15:00 PM
“What the industry really needs for the next generation are compounds that work on more than one target, because this will really accelerate progress against disease”

 
[RxPG] Designer molecules that combine metals such as copper with natural organic materials could one day attack viruses in the body and treat a wide range of diseases.That's the finding of chemists at Ohio State University, who have successfully tested such molecules against portions of HIV and Hepatitis C virus RNA in the laboratory. They've also created molecules that act like ACE, or angiotensin-converting enzyme, inhibitors – drugs that are used to lower blood pressure.

At the American Chemical Society national meeting in Washington, DC, project leader James Cowan described how the same patent-pending technology could one day produce novel anti-tumor agents.

Drugs based on these molecules could produce fewer side effects compared to some of today's treatments, and they could also combat drug resistance, said Cowan, professor of chemistry at Ohio State.Pharmaceutical companies tend to make drugs from the same limited set of ingredients, drawing upon only about a half-dozen of the more than 100 known chemical elements, Cowan explained. At the same time, drug-resistant bacteria and viruses are emerging.

“We have to start broadening the landscape of drug design.”

His new molecules, called metal coordination complexes, mimic the activity of natural enzymes that break apart DNA, RNA, and proteins in the body.

Cowan and his colleagues have tailor-made different complexes to break apart portions of RNA that enable HIV and Hepatitis C viruses to function, as well as the ACE enzyme that constricts blood vessels in the body. In test tubes and in cell cultures of E. coli, the complexes targeted these particular RNA structures and enzymes and destroyed them.

The complexes work in one of two ways. Some use a process called redox chemistry to steal electrons from the bonds holding the target molecule together. “Most drugs are designed to inhibit – that is, they will bind to a protein molecule and just block its function,” Cowan said. “But with metals you have the option of completely destroying the target.”

Metals can be toxic, but so can some organic molecules that are used as drugs, Cowan pointed out.

One of these complexes could destroy a target, and then move on to another, eventually destroying many targets. So a smaller dose of a metal complex could do the work of a larger dose of a traditional drug.

Completely destroying the target molecule also lowers the chance that a virus will develop a drug-resistant strain.

The chemists are also working on metal-free versions of their molecules that will assemble themselves on site, by harvesting the metal that is naturally present in cells. One of the potential obstacles to using metals as drugs is that the Food and Drug Administration doesn't yet have streamlined procedures for approving the compounds. But Cowan is confident that the situation will soon change, given the need for alternatives to traditional drugs.

He feels that these metal complexes represent a good first step toward the development of multi-functional drugs called dual-activity agents.

Today, people often must take several drugs to combat different cardiovascular enzymes. One dual-activity drug could do the work of two, by lowering blood pressure and simultaneously reducing the formation of arterial plaque.



Publication: American Chemical Society national meeting in Washington, DC
On the web: www.chemistry.ohio-state.edu 

Advertise in this space for $10 per month. Contact us today.


Related Pharmacology News
Palliative radiotherapy for bone metastases in elderly patients improves quality of life
Research shows promise for microwave ablation to relieve painful bone and soft-tissue tumors
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia
Research examines effects of opioids on patients with sickle cell disease
Full range of treatment settings and their effects on radiofrequency heat lesion size
High-dose opioids disturb hormones long-term, but mental and physiologic function improves
Web-based tools found to enhance recruitment and prescreening for clinical pain trials
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study: Pain improves during first year but mental-health problems linger

Subscribe to Pharmacology Newsletter

Enter your email address:


 Additional information about the news article
This work was funded by the National Institutes of Health.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)